Asthma Inhaler Device Market

As per Market Research Future Analysis, the Asthma Inhaler Device Market was valued at USD 1.40 Billion in 2023 and is projected to grow to USD 3.07 Billion by 2032, with a CAGR of 7.97% from 2024 to 2032. The market is driven by the increasing prevalence of asthma, particularly among children, and the rising awareness of respiratory conditions. The COVID-19 pandemic has further exacerbated breathing issues, leading to a higher demand for inhaler devices. Key products include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, which are essential for managing asthma and COPD. The market is characterized by significant investments in research and development by major players to innovate and improve inhalation devices.

GlaxoSmithKline plc (UK), Koninklijke Philips NV (Netherlands), AstraZeneca (UK), Cipla Inc. (India), Boehringer Ingelheim International GmbH (Germany), Beximco Pharmaceuticals Ltd (Bangladesh), Merck & Co., Inc. (the US), Teva Pharmaceutical Industries Ltd (Israel), Chiesi Farmaceutici SpA (Italy), Medisol Lifescience Pvt. Ltd (India).

• Q2 2024: AstraZeneca receives FDA approval for Airsupra (albuterol/budesonide) inhaler for asthma AstraZeneca announced that the U.S. FDA has approved its Airsupra inhaler, a combination of albuterol and budesonide, for the treatment of asthma in adults, marking a significant regulatory milestone for the company’s respiratory portfolio.
• Q2 2024: Teva and MedinCell announce U.S. launch of new digital inhaler for asthma management Teva Pharmaceuticals and MedinCell launched a new digital inhaler in the U.S. market, featuring integrated sensors to track patient usage and improve adherence for asthma patients.
• Q3 2024: GSK opens new manufacturing facility for Ellipta inhalers in Singapore GlaxoSmithKline inaugurated a new state-of-the-art facility in Singapore dedicated to the production of Ellipta inhalers, expanding its global manufacturing footprint for respiratory devices.
• Q3 2024: Propeller Health partners with Novartis to integrate smart inhaler technology into Enerzair Breezhaler Propeller Health and Novartis announced a partnership to incorporate Propeller’s digital sensor technology into Novartis’s Enerzair Breezhaler, aiming to enhance asthma management through real-time data tracking.
• Q4 2024: Viatris completes acquisition of inhaler device assets from Theravance Biopharma Viatris finalized the acquisition of select inhaler device assets from Theravance Biopharma, strengthening its portfolio in the asthma and respiratory device market.
• Q4 2024: AstraZeneca launches Symbicort digital inhaler in Europe AstraZeneca announced the commercial launch of its Symbicort digital inhaler in several European countries, featuring connectivity for patient monitoring and adherence support.
• Q1 2025: ResMed acquires inhaler startup AirFlow for $120 million ResMed completed the acquisition of AirFlow, a startup specializing in smart inhaler technology for asthma, in a deal valued at $120 million to expand its respiratory care offerings.
• Q1 2025: Novartis receives EMA approval for Enerzair Breezhaler triple therapy inhaler Novartis announced that the European Medicines Agency (EMA) has approved its Enerzair Breezhaler triple therapy inhaler for asthma, enabling broader access to combination treatment in Europe.
• Q2 2025: Philips launches new portable dry powder inhaler for asthma in Asia-Pacific Philips introduced a new portable dry powder inhaler for asthma patients in the Asia-Pacific region, designed for improved drug delivery and patient convenience.
• Q2 2025: Chiesi secures FDA approval for environmentally friendly inhaler propellant Chiesi Group received FDA approval for its new asthma inhaler using a low global warming potential propellant, supporting sustainability initiatives in respiratory care.
• Q3 2025: HealthTech startup Inhalo raises $35M Series B to develop next-gen smart inhalers Inhalo, a HealthTech startup focused on smart inhaler devices for asthma, closed a $35 million Series B funding round to accelerate product development and commercialization.
• Q3 2025: GSK announces partnership with Apple to integrate inhaler data into HealthKit GlaxoSmithKline entered a partnership with Apple to enable data from GSK’s asthma inhalers to be integrated into Apple’s HealthKit platform, allowing patients and clinicians to monitor inhaler usage more effectively.

Regional analysis

The regional Asthma Inhaler Device Market is broadly divided into the Americas, Europe, Asia-Pacific and the MEA.

Among all these regional Asthma Inhaler Device Market s, America is expected to be the most dominating region due to the increasing cases of asthma in the region. The rising demand for metered-dose inhaler and smart inhalers along with the technological advancements are providing a boost to the American Asthma Inhaler Device Market . Europe is expected to be the second largest region of the Asthma Inhaler Device Market during the forecast period. European Academy of Allergy & Clinical Immunology is making constant efforts to make people aware of the problem.

The rising awareness among people and hospitals and patients adopting respiratory inhalers are driving the growth of the European Asthma Inhaler Device Market . In Asia-Pacific regional Asthma Inhaler Device Market is growing due to the rising prevalence of asthma in countries like India, china and Japan. The MEA is also expecting a steady growth because of the rising cases of asthma and demand  for better treatment.

Competitive landscape

The global Asthma Inhaler Device Market is highly competitive with the presence of many prominent key players in the Asthma Inhaler Device Market . To sustain in the completion of the Asthma Inhaler Device Market , the key players are embracing various strategies such as collaboration with other players, partnership, product launch, merger and acquisition and investment in research and developments.

Major key players

• GlaxoSmithKline plc (UK)
• Koninklijke Philips NV (Netherlands)
• AstraZeneca (UK)
• Cipla Inc. (India)
• Boehringer Ingelheim International GmbH (Germany)
• Beximco Pharmaceuticals Ltd (Bangladesh)
• Merck & Co., Inc. (the US)
• Teva Pharmaceutical Industries Ltd (Israel)
• Chiesi Farmaceutici SpA (Italy)
• and Medisol Lifescience Pvt. Ltd (India)